Extended-release opioids in the management of cancer pain: A systematic review of efficacy and safety

European Journal of Pain (United Kingdom)

Volumn 18, Issue 5, 2014, Pages 605-616

  Mesgarpour, B ^a   Griebler, U ^b   Glechner, A ^b   Kien, C ^b   Strobelberger, M ^b   Van Noord, M G ^b   Michalek Sauberer, A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE; NALOXONE; NALOXONE PLUS OXYCODONE; OPIATE; OXYCODONE; DELAYED RELEASE FORMULATION; NARCOTIC ANALGESIC AGENT;

BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL EFFECTIVENESS; COGNITION; CONSTIPATION; CONTROLLED DRUG RELEASE; DIZZINESS; DROWSINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EXTENDED DRUG RELEASE; FATIGUE; FUNCTIONAL STATUS; HUMAN; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; ANALGESIA; COMPLICATION; DELAYED RELEASE FORMULATION; META ANALYSIS; NEOPLASM; PAIN; PROCEDURES; PSYCHOLOGY;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; HUMANS; NEOPLASMS; PAIN; PAIN MANAGEMENT; QUALITY OF LIFE;

EID: 84898976358     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/j.1532-2149.2013.00401.x     Document Type: Review

References (25)

1. Ahmedzai, S.H., Nauck, F., Bar-Sela, G., Bosse, B., Leyendecker, P., Hopp, M., (2012). A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 26, 50-60.
2. Bennett, M.I., Graham, J., Schmidt-Hansen, M., Prettyjohns, M., Arnold, S., (2012). Prescribing strong opioids for pain in adult palliative care: Summary of NICE guidance. BMJ 344, e2806.
3. Caraceni, A., Hanks, G., Kaasa, S., Bennett, M.I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D.F., Juhl, G., King, S., Klepstad, P., Laugsand, E.A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., Reid, C., Sjogren, P., Stone, P.C., Tassinari, D., Zeppetella, G., EPCRC, EAPC, (2012). Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol 13, e58-e68.
4. Deeks, J.J., Dinnes, J., D'Amico, R., Sowden, A.J., Sakarovitch, C., Song, F., Petticrew, M., Altman, D.G., (2003). Evaluating non-randomised intervention studies. Health Technol Assess 7, 1-173.
5. Green, C.R., Hart-Johnson, T., Loeffler, D.R., (2011). Cancer-related chronic pain: Examining quality of life in diverse cancer survivors. Cancer 117, 1994-2003.
6. Green, E., Zwaal, C., Beals, C., Fitzgerald, B., Harle, I., Jones, J., Tsui, J., Volpe, J., Yoshimoto, D., Wiernikowski, J., (2010). Cancer-related pain management: A report of evidence-based recommendations to guide practice. Clin J Pain 26, 449-462.
7. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., Schunemann, H.J., (2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924-926.
8. Hagen, N.A., Babul, N., (1997). Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79, 1428-1437.
9. Hanna, M., Thipphawong, J., (2008). A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 7, 17.
10. Hartung, D.M., Middleton, L., Haxby, D.G., Koder, M., Ketchum, K.L., Chou, R., (2007). Rates of adverse events of long-acting opioids in a state Medicaid program. Ann Pharmacother 41, 921-928.
11. Higgins, J.P.T., Green, S., (2011). Cochrane Handbook for Systematic Reviews of Interventions.
12. Lawlor, P., (2003). Multidimensional assessment: Pain and palliative care. In Cancer Pain: Assessment and Management, E. Bruera, R. Portenoy, eds. (Cambridge: Cambridge University Press) pp. 67-69.
13. Mercadante, S., Porzio, G., Ferrera, P., Aielli, F., Adile, C., Ficorella, C., (2010). Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin 26, 2765-2768.
14. Mercadante, S., Porzio, G., Ferrera, P., Fulfaro, F., Aielli, F., Verna, L., Villari, P., Ficorella, C., Gebbia, V., Riina, S., Casuccio, A., Mangione, S., (2008). Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 12, 1040-1046.
15. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6, e1000097.
16. Mystakidou, K., Tsilika, E., Parpa, E., Katsouda, E., Galanos, A., Vlahos, L., (2006). Psychological distress of patients with advanced cancer: Influence and contribution of pain severity and pain interference. Cancer Nurs 29, 400-405.
17. Okamoto, Y., Tsuneto, S., Tsugane, M., Takagi, T., Uejima, E., (2010). A retrospective chart review of opioid-induced nausea and somnolence on commencement for cancer pain treatment. J Opioid Manag 6, 431-434.
18. Paice, J.A., Ferrell, B., (2011). The management of cancer pain. CA Cancer J Clin 61, 157-182.
19. Schneider, J.P., (2008). Role of SR opioids in treating chronic pain. Pract Pain Manage 8, 68-70.
20. Shuman, A.G., Terrell, J.E., Light, E., Wolf, G.T., Bradford, C.R., Chepeha, D., Jiang, Y., McLean, S., Ghanem, T.A., Duffy, S.A., (2012). Predictors of pain among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 138, 1147-1154.
21. Solberg Nes, L., Liu, H., Patten, C.A., Rausch, S.M., Sloan, J.A., Garces, Y.I., Cheville, A.L., Yang, P., Clark, M.M., (2012). Physical activity level and quality of life in long term lung cancer survivors. Lung Cancer 77, 611-616.
22. van Seventer, R., Smit, J.M., Schipper, R.M., Wicks, M.A., Zuurmond, W.W., (2003). Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 19, 457-469.
23. Wirz, S., Wartenberg, H.C., Nadstawek, J., (2008). Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support Care Cancer 16, 999-1009.
24. Wirz, S., Wittmann, M., Schenk, M., Schroeck, A., Schaefer, N., Mueller, M., Standop, J., Kloecker, N., Nadstawek, J., (2009). Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 13, 737-743.
25. World Health Organization. (1996). Cancer Pain Relief with a Guide to Opioid Availability (Geneva, Switzerland: WHO).